0001193125-17-170837.txt : 20170515 0001193125-17-170837.hdr.sgml : 20170515 20170515171533 ACCESSION NUMBER: 0001193125-17-170837 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 6 FILED AS OF DATE: 20170515 DATE AS OF CHANGE: 20170515 EFFECTIVENESS DATE: 20170515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001590750 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 471187261 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36483 FILM NUMBER: 17845796 BUSINESS ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 303-531-5952 MAIL ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUDICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: SIGNAL GENETICS, INC. DATE OF NAME CHANGE: 20140710 FORMER COMPANY: FORMER CONFORMED NAME: SIGNAL GENETICS LLC DATE OF NAME CHANGE: 20131031 DEFA14A 1 d392509ddefa14a.htm DEFA14A DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.    )

 

 

Filed by the Registrant  ☒                             Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material under §240.14a-12

Miragen Therapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

  No fee required.
  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  (1)  

Title of each class of securities to which transaction applies:

 

     

  (2)  

Aggregate number of securities to which transaction applies:

 

     

  (3)  

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

  (4)  

Proposed maximum aggregate value of transaction:

 

     

  (5)  

Total fee paid:

 

     

  Fee paid previously with preliminary materials.
  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  (1)  

Amount Previously Paid:

 

     

  (2)  

Form, Schedule or Registration Statement No.:

 

     

  (3)  

Filing Party:

 

     

  (4)  

Date Filed:

 

     

 

 

 


*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the

Stockholder Meeting to Be Held on June 28, 2017.

 

MIRAGEN THERAPEUTICS, INC.

 

MIRAGEN THERAPEUTICS, INC.

C/O PROXY SERVICES

P.O. BOX 9142

FARMINGDALE, NY 11735

 

LOGO

 

Meeting Information

Meeting Type:           Annual Meeting

 

For holders as of:      May 5, 2017

 

Date: June 28, 2017        Time:    9:00 AM, Mountain Time

 

Location:  Element Bistro

   6315 Lookout Road

   Boulder, CO 80301

 

You are receiving this communication because you hold shares in the company named above.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

 

See the reverse side of this notice to obtain proxy materials and voting instructions.

 


 

—  Before You Vote  —

How to Access the Proxy Materials

 

 

 

Proxy Materials Available to VIEW or RECEIVE:

 

NOTICE AND PROXY STATEMENT            FORM 10-K

 

 

How to View Online:

 

 

Have the information that is printed in the box marked by the arrow LOGO (located on the following page) and visit: www.proxyvote.com.

 

 

How to Request and Receive a PAPER or E-MAIL Copy:

 

 

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

 

 

1) BY INTERNET:          www.proxyvote.com

 

2) BY TELEPHONE:      1-800-579-1639

 

3) BY E-MAIL*:              sendmaterial@proxyvote.com

 

 

*  If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow LOGO (located on the following page) in the subject line.

 

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before June 14, 2017 to facilitate timely delivery.

 

 

 

—  How To Vote  —

Please Choose One of the Following Voting Methods

 

 

LOGO

 

 

Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. You can obtain directions to the meeting location by visiting www.miragentherapeutics.com.

 

 

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow LOGO (located on the following page) available and follow the instructions.

 

 

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

 


Voting Items          

The Board of Directors recommends you vote FOR

all nominees listed and FOR Proposal 2.

 

  1. Election of Directors

 

Nominees:

 

     
01)   William S. Marshall, Ph.D.   05)   Kevin Koch, Ph.D.  
02)   Bruce L. Booth, Ph.D.   06)   Kyle A. Lefkoff  
03)   John W. Creecy   07)   Joseph L. Turner  
04)   Thomas E. Hughes, Ph.D.      

 

  2. To ratify the selection by our Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the company for its fiscal year ending December 31, 2017.

NOTE: In their discretion, the proxyholders are authorized to vote upon such other matters that may properly come before the meeting or any adjournment or adjournments thereof.

 

LOGO


 

 

 

 

 

 

LOGO

GRAPHIC 2 g392509naaarrow.jpg GRAPHIC begin 644 g392509naaarrow.jpg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end GRAPHIC 3 g392509naapg01.jpg GRAPHIC begin 644 g392509naapg01.jpg M_]C_X 02D9)1@ ! @ 9 !D #_[ 11'5C:WD 0 $ 9 _^X #D%D M;V)E &3 ?_; (0 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# P,#_\ $0@ 2P * P$1 (1 0,1 ?_$ (4 (" P M <(!@D! PH! 0$! " 1 4! P8)" L M P0%!@<" 34( !1D%18V$316-U<8.%@Y,1)B$V,F%V=183,D9:5FIBAI MV1$! (" @, $1(3%!85&1P?_: P# 0 "$0,1 #\ ZYU6 M#\5SM>:LO*N(&3F2T51U3J<<#68JNPBQL%%0G"&%A8IC01192[2BE=D+*QW2 M6,F**EA6MHI.>L*TUEZS<,[48]>0Z+X>.U/V+,[>_(C>&Y/1N32\C BL=F% MZ_Y75)D?^+B,22[-,C3_B-C.#!59GN@2-G&@L%\QQ+Q6*&D@6OIOG- M6I2V,AJ]51BJDN4J+4A6V&YZ6,[)L#E&X.;#9/G7?6XG*3>V_P#]6WWI^1E2 M14*1<0H2N\6-%$"PNFQ+\T6D M^7T,B09D?"V$V7Y&[Q84TXG/6J.)"1E!+3([MP_J*%#R]/8;\7)0' MFN&VF$IJ)@(0HKGS-)48V7X!:*@0;*5JNXJ?!]-CE[I0?6X>Q_%(]OSI.W$W MZ]EN_P#A>1*J!4(8:HI>;R*!2+/T9S$YYRG=Q*6(##5&4OG6!:KKJ?3FW>9C.[H:-Y M=.MX[NZ)='MLB53GXT>]],R)0^8HH<[HF!T.R28LQ).:4T]V+ED,.F%(_PK+T9$6:65 M![8TL#7Y/1C:D57"Z-FNOML1J0Z%?.LQX$[-,M5>,'/_ )F_)#LG\'E GRAPHIC 4 g392509naapg02.jpg GRAPHIC begin 644 g392509naapg02.jpg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end GRAPHIC 5 g392509naapg03.jpg GRAPHIC begin 644 g392509naapg03.jpg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end GRAPHIC 6 g392509naapg04.jpg GRAPHIC begin 644 g392509naapg04.jpg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